Furthermore, patient-derived in vitro models demonstrated ADCC as a major therapeutic mechanism of rituximab in non-Hodgkin lymphoma and anti-CD38 antibodies in multiple myeloma [45,46]. Here, CD38 is linked to plasma cell myeloma.